A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

MLA

Tomoya Ohno, et al. A Phase 1 Clinical Trial of the Selective BTK Inhibitor ONO/GS-4059 in Relapsed and Refractory Mature B-Cell Malignancies. Jan. 2016. EBSCOhost, https://doi.org/10.1182/blood-2015-08-664086⟩.

APA

Tomoya Ohno, Claire V. Hutchinson, John Sharpe, Guillaume Cartron, Gilles Salles, Simon Rule, Franck Morschhauser, Hideyuki Honda, Bruno Cazin, Virginia Jamieson, Shin-ichiro Abe, Lionel Karlin, Toshio Yoshizawa, Harriet S. Walter, Akihisa Nishimura, Philippe Quittet, Martin J. S. Dyer, Kevin J. Duffy, Nimish Shah, … Nigel Courtenay-Luck. (2016). A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. https://doi.org/10.1182/blood-2015-08-664086⟩

Chicago

Tomoya Ohno, Claire V. Hutchinson, John Sharpe, Guillaume Cartron, Gilles Salles, Simon Rule, Franck Morschhauser, et al. 2016. “A Phase 1 Clinical Trial of the Selective BTK Inhibitor ONO/GS-4059 in Relapsed and Refractory Mature B-Cell Malignancies,” January. doi:10.1182/blood-2015-08-664086⟩.